Last reviewed · How we verify
NCT05554094
Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder
Active, enrolled
Phase 2
Last updated 4 March 2026
What this trial tests
Phase 2 trial testing Psilocybin in PTSD in 15 participants. Participants enrolled and being followed up; not accepting new ones.
Timeline
1 January 2023
Primary endpoint
31 December 2025
31 December 2025
31 July 2026
Quick facts
| Lead sponsor | Ohio State University |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 1 January 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 July 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Psilocybin — full drug profile →
Conditions studied
- PTSD — all drugs for PTSD →
- Stress Disorders, Traumatic — all drugs for Stress Disorders, Traumatic →
- Stress Disorders, Post-Traumatic — all drugs for Stress Disorders, Post-Traumatic →
- Trauma and Stressor Related Disorders — all drugs for Trauma and Stressor Related Disorders →
Sponsor
Ohio State University
Who can join
Adults 21 to 64, any sex, with PTSD or Stress Disorders, Traumatic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary aim of this study is to assess the safety and efficacy of psilocybin-assisted therapy in the treatment of post-traumatic stress disorder in United States military Veterans.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism.
Mitchell JM, Anderson BT. · · 2024 · cited 32× · PMID 37479859 · DOI 10.1038/s41386-023-01656-7 -
Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020.
Kopra EI, Ferris JA, Winstock AR, Kuypers KP, et al · · 2023 · cited 32× · PMID 36876583 · DOI 10.1177/02698811231158245 -
Psilocybin Facilitates Fear Extinction: Importance of Dose, Context, and Serotonin Receptors.
Woodburn SC, Levitt CM, Koester AM, Kwan AC. · · 2024 · cited 22× · PMID 39087917 · DOI 10.1021/acschemneuro.4c00279 -
Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD.
Davis AK, Levin AW, Nagib PB, Armstrong SB, et al · · 2023 · cited 11× · PMID 37142308 · DOI 10.1136/bmjopen-2022-068884
Verify or expand the search:
- PubMed search for NCT05554094
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Psilocybin
Trials testing the same drug.
- NCT06885996 — Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence · Phase 2 · not yet recruiting
- NCT07499583 — Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder · Phase 1, PHASE2 · not yet recruiting
- NCT07226232 — Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression · Phase 3 · not yet recruiting
- NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
- NCT07506395 — Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder · Phase 1 · not yet recruiting
Other recruiting trials for PTSD
Currently open trials in the same condition.
- NCT07473505 — Integrative Bilateral Cervical Sympathetic Blocks for Trauma-Related Symptoms in Special Operations Veterans: A Prospect · recruiting
- NCT07010757 — Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial · NA · recruiting
- NCT07372586 — Behavioral Health Collaborative Care Model in an ICU Recovery Clinic · NA · recruiting
- NCT07390786 — Behavioral Health Collaborative Care Model in Post-ICU Clinic Family Pilot · NA · recruiting
- NCT07469098 — Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events · Phase 2 · recruiting
Other Ohio State University trials
Trials by the same sponsor.
- NCT06542458 — Under-Represented Communities Diagnosed With SCD or MCI Through Tele-Cog · not yet recruiting
- NCT07217548 — Solving Stigma Through POV Simulation: Enhancing Pharmacist Empathy-based Practices With Sickle Cell Disease Patients · NA · enrolling by invitation
- NCT07215221 — Implementation of TBI-RECOVER in Substance Use Treatment · NA · not yet recruiting
- NCT07278427 — Reducing Parental Substance Use and Enhancing Family Resilience Among Rural Families Through Ohio START · recruiting
- NCT07490444 — Metric-Optimized Spectacle Prescriptions for Children With Down Syndrome · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT05554094 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ohio State University
- Last refreshed: 4 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05554094.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing